December 4, 2022
Loading...
You are here:  Home  >  Health Care & Life Science  >  Current Article

FDA decides not to approve Amgen biosimilar, at least for now

IN THIS ARTICLE

Amgen’s ABP980, a biosimilar of Genentech's cancer treatment Herceptin, was denied approval by the U.S. Food and Drug Administration, the company announced June 1. The Thousand Oaks biotech giant said it received a complete response letter from the FDA. The letters are sent out if the agency has decided not to approve a drug, containing…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.